Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 25:39:101085.
doi: 10.1016/j.ymgmr.2024.101085. eCollection 2024 Jun.

Acid α-glucosidase (GAA) activity and glycogen content in muscle biopsy specimens of patients with Pompe disease: A systematic review

Affiliations

Acid α-glucosidase (GAA) activity and glycogen content in muscle biopsy specimens of patients with Pompe disease: A systematic review

Benedikt Schoser et al. Mol Genet Metab Rep. .

Abstract

Pompe disease is a rare genetic disorder characterized by a deficiency of acid α-glucosidase (GAA), leading to the accumulation of glycogen in various tissues, especially in skeletal muscles. The disease manifests as a large spectrum of phenotypes from infantile-onset Pompe disease (IOPD) to late-onset Pompe disease (LOPD), depending on the age of symptoms onset. Quantifying GAA activity and glycogen content in skeletal muscle provides important information about the disease severity. However, the distribution of GAA and glycogen levels in skeletal muscles from healthy individuals and those impacted by Pompe disease remains poorly understood, and there is currently no universally accepted standard assay for GAA activity measurement. This systematic literature review aims to provide an overview of the available information on GAA activity and glycogen content levels in skeletal muscle biopsies from patients with Pompe disease. A structured review of PubMed and Google Scholar literature (with the latter used to check that no additional publications were identified) was conducted to identify peer-reviewed publications on glycogen storage disease type II [MeSH term] + GAA, protein human (supplementary concept), Pompe, muscle; and muscle, acid alpha-glucosidase. A limit of English language was applied. Results were grouped by methodologies used to quantify GAA activity and glycogen content in skeletal muscle. The search and selection strategy were devised and carried out in line with Preferred Reporting of Items in Systematic Reviews and Meta-Analysis guidelines and documented using a flowchart. Bibliographies of papers included in the analysis were reviewed and applicable publications not already identified in the search were included. Of the 158 articles retrieved, 24 (comprising >100 muscle biopsies from >100 patients) were included in the analysis, with four different assays. Analysis revealed that patients with IOPD exhibited markedly lower GAA activity in skeletal muscles than those with LOPD, regardless of the measurement method employed. Additionally, patients with IOPD had notably higher glycogen content levels in skeletal muscles than those with LOPD. In general, however, it was difficult to fully characterize GAA activity because of the different methods used. The findings underscore the challenges in the interpretation and comparison of the results across studies because of the substantial methodological variations. There is a need to establish standardized reference ranges of GAA activity and glycogen content in healthy individuals and in Pompe disease patients based on globally standardized methods to improve comparability and reliability in assessing this rare disease.

Keywords: Acid α-glucosidase; Glycogen; Pompe disease; Skeletal muscle biopsy.

PubMed Disclaimer

Conflict of interest statement

B. Schoser reports: advisory board: Amicus, Astellas, Bayer, Maze, Sanofi, Taysha. Unrestricted Contracted Research; Amicus, Astellas. Honoraria; Kedrion, Alexion, Argenx, Spark. Travel Expenses; Astellas, Amicus, Sanofi. N. Raben is an employee of M6P Therapeutics. F. Varfaj reports no competing interests. M. Walzer is an employee of Astellas Gene Therapies. A. Toscano reports no competing interests.

Figures

Fig. 1
Fig. 1
PRISMA flow diagram. The flow chart includes one review article that was used for the bibliography review, but then subsequenctly removed from the analysis. GAA: acid α-glucosidase; IOPD: infantile-onset Pompe disease; LOPD: late-onset Pompe disease.

Similar articles

Cited by

References

    1. Güngör D., de Vries J.M., Hop W.C., Reuser A.J., van Doorn P.A., van der Ploeg A.T., Hagemans M.L. Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy. Orphanet J. Rare Dis. 2011;6:34. https://pubmed.ncbi.nlm.nih.gov/21631931/ - PMC - PubMed
    1. Hagemans M.L., Winkel L.P., Van Doorn P.A., Hop W.J., Loonen M.C., Reuser A.J., Van der Ploeg A.T. Clinical manifestation and natural course of late-onset Pompe’s disease in 54 Dutch patients. Brain. 2005;128:671–677. https://pubmed.ncbi.nlm.nih.gov/15659425/ - PubMed
    1. Montagnese F., Barca E., Musumeci O., Mondello S., Migliorato A., Ciranni A., Rodolico C., De Filippi P., Danesino C., Toscano A. Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment. J. Neurol. 2015;262:968–978. https://pubmed.ncbi.nlm.nih.gov/25673129/ - PubMed
    1. A. Schüller, S. Wenninger, N. Strigl-Pill, B. Schoser, Toward deconstructing the phenotype of late-onset Pompe disease, Am. J. Med. Genet. C: Semin. Med. Genet. 160c (2012) 80–88. https://pubmed.ncbi.nlm.nih.gov/22253010/. - PubMed
    1. van der Beek N.A., van Capelle C.I., van der Velden-van Etten K.I., Hop W.C., van den Berg B., Reuser A.J., van Doorn P.A., van der Ploeg A.T., Stam H. Rate of progression and predictive factors for pulmonary outcome in children and adults with Pompe disease. Mol. Genet. Metab. 2011;104:129–136. https://pubmed.ncbi.nlm.nih.gov/21763167/ - PubMed

LinkOut - more resources